Stellaria Media

Dosage for Stellaria Media allergenic extracts is highly individualized and must be determined by an allergist based on the patient's sensitivity level and clinical history. There is no 'one-size-fits-all' dose.

• Diagnostic Testing: For skin prick testing, a single drop of a 1:10 or 1:20 w/v (weight/volume) concentration is typically applied. For intradermal testing, 0.02 mL of a much more dilute concentration (e.g., 100 PNU/mL) may be injected.
• Immunotherapy (Build-up Phase): Treatment usually begins with a very low dose, such as 0.05 mL of a 1:100,000 dilution. Doses are increased weekly or bi-weekly by 50% to 100% until the 'Maintenance Dose' is reached.
• Maintenance Phase: Once the maintenance dose is reached (typically 0.5 mL of a 1:100 or 1:20 concentration), the interval between injections is extended to every 2 to 4 weeks.

Stellaria Media extracts are used in children, but extreme caution is required. Pediatric dosing follows the same 'start low and go slow' principle used in adults. Clinical studies suggest that children as young as 5 years old can safely undergo immunotherapy, provided they are monitored closely. Doses are adjusted based on the child's systemic reaction history rather than weight-based formulas used for other medications.

Renal Impairment

No specific dose adjustments are typically required for renal impairment, as the proteins are metabolized proteolytically. However, patients with severe renal disease may be at higher risk if systemic reactions occur, as their physiological reserve to handle anaphylaxis may be lower.

Hepatic Impairment

No adjustments are necessary for hepatic impairment. The liver's CYP450 system is not involved in the clearance of these allergenic proteins.

Elderly Patients

Elderly patients (over 65) should be evaluated for cardiovascular stability before starting Stellaria Media immunotherapy. If an elderly patient is taking beta-blockers for hypertension, the use of this extract may be contraindicated (see Interactions).

Stellaria Media extracts for immunotherapy are administered via subcutaneous injection, usually in the posterior aspect of the upper arm.

• Preparation: The vial should be inspected for particulate matter or discoloration.
• Administration: The injection must be subcutaneous, not intramuscular or intravenous. Accidental intravenous injection significantly increases the risk of a systemic reaction.
• Observation: Patients MUST remain in the medical office for at least 30 minutes following any injection of Stellaria Media to be monitored for signs of anaphylaxis.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose in the immunotherapy schedule is missed, the next dose may need to be reduced to avoid a systemic reaction due to a loss of tolerance.

• If 1 week is missed: Repeat the last dose.
• If 2-3 weeks are missed: Reduce the dose by 1 to 2 increments.
• If more than 4 weeks are missed: Consult the allergist; the build-up may need to be restarted from a much lower concentration.

An overdose of Stellaria Media extract (either too high a concentration or too large a volume) typically manifests as a severe systemic allergic reaction or anaphylaxis.

• Symptoms: Generalized itching, hives, swelling of the throat, wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency of administration without medical guidance.

The most frequent side effects associated with Stellaria Media extracts are localized to the site of administration. These are expected pharmacological responses to the allergen.

• Local Redness (Erythema): A red patch at the injection site that may appear within minutes and last for several hours.
• Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is larger than the size of a half-dollar (approx. 3 cm), it should be reported to the physician before the next dose.
• Itching (Pruritus): Intense itching at the site of the skin test or injection.
• Tenderness: The area may feel sore or warm to the touch for 24-48 hours.

These reactions are more widespread but not necessarily life-threatening:

• Generalized Hives (Urticaria): Itchy bumps appearing on parts of the body away from the injection site.
• Nasal Congestion: Sneezing or a runny nose shortly after the injection.
• Mild Cough: A persistent dry cough or 'tickle' in the throat.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy session.

• Angioedema: Deep tissue swelling, particularly around the eyes, lips, or tongue.
• Wheezing or Bronchospasm: Difficulty breathing or a whistling sound when exhaling, particularly in patients with pre-existing asthma.
• Vasovagal Reactions: Fainting or lightheadedness, often due to the needle stick rather than the extract itself.

> Warning: Stop taking Stellaria Media and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:

1. 1Difficulty Breathing: Feeling as though your airway is closing or severe shortness of breath.
2. 2Throat Tightness: A hoarse voice or difficulty swallowing.
3. 3Rapid or Weak Pulse: Signs of cardiovascular collapse.
4. 4Severe Dizziness: Feeling like you are going to pass out, which may indicate a drop in blood pressure.
5. 5Nausea and Vomiting: Sudden, severe gastrointestinal distress following an injection is often a sign of a systemic allergic reaction.
6. 6Cyanosis: Bluish tint to the lips or fingernails.

With prolonged use of Stellaria Media in immunotherapy (typically 3-5 years), the primary 'side effect' is the intended modulation of the immune system. However, some patients may develop 'delayed local reactions,' where swelling appears 6-12 hours after the injection. There is no evidence that long-term use of these extracts causes autoimmune diseases or malignancy. In rare cases, chronic local irritation can lead to small areas of subcutaneous fibrosis (scarring) at frequent injection sites.

While Stellaria Media specifically may not have an individual black box warning for every manufacturer, the entire class of Allergenic Extracts carries a general FDA-mandated warning regarding the risk of severe non-fatal and fatal systemic reactions.

Summary of Warning:

• This product can cause severe life-threatening systemic reactions, including anaphylaxis.
• It should only be administered in a setting where emergency equipment and trained personnel are available.
• Patients with unstable asthma are at increased risk for fatal reactions.
• Patients must be observed for at least 30 minutes after administration.

Report any unusual symptoms to your healthcare provider. Even a 'small' systemic reaction (like a few hives) can predict a much more severe reaction at the next dose.

Stellaria Media extracts are potent biological agents that must be handled with extreme care. They are not intended for self-administration by the patient at home unless specifically trained and authorized under a very strict protocol (which is rare for this specific extract). The primary safety concern is the unpredictable nature of allergic sensitivity, which can fluctuate based on the patient's current health, recent allergen exposure, and even the weather.

No specific FDA black box warning exists solely for the Stellaria Media plant species; however, it falls under the Class-Wide Black Box Warning for Allergenic Extracts. This warning emphasizes that these products are intended for use only by physicians experienced in administering allergenic extracts and that they can cause anaphylaxis. It also notes that the risk is higher in patients with high degrees of sensitivity or those receiving injections during peak pollen seasons.

• Anaphylaxis Risk: This is the most significant risk. Patients must be screened for 'high-risk' factors, such as a history of severe asthma or previous systemic reactions to skin testing.
• Asthma Exacerbation: Stellaria Media should never be administered to a patient experiencing an acute asthma flare-up. The patient's FEV1 (Forced Expiratory Volume) should ideally be checked if they feel short of breath prior to the injection.
• Infection/Illness: Injections should be deferred if the patient has a fever or a significant respiratory infection, as this can lower the threshold for a systemic reaction.
• Injection Technique: Healthcare providers must aspirate the syringe before injecting to ensure the needle is not in a blood vessel.

• Pre-Injection Assessment: The clinician must ask about the patient's reaction to the previous dose and their current asthma status.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is standard.
• Peak Flow Monitoring: For asthmatic patients, monitoring peak expiratory flow rates before and after injections may be required.
• Lab Tests: While routine blood work is not needed for the drug itself, clinicians may monitor serum tryptase levels if a severe systemic reaction occurs to confirm the diagnosis of anaphylaxis.

Stellaria Media does not directly cause sedation. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, their ability to drive will be severely impaired. It is generally advised to wait until the 30-minute observation period is over and the patient feels completely normal before they drive.

Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation and may increase the rate of allergen absorption or mask the early symptoms of an allergic reaction.

If a patient experiences a life-threatening reaction to Stellaria Media, the therapy is typically discontinued permanently. If the patient decides to stop therapy for other reasons, there is no 'withdrawal' syndrome, but the allergic symptoms that the therapy was treating will likely return over time as the immunological tolerance fades.

> Important: Discuss all your medical conditions with your healthcare provider before starting Stellaria Media.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These drugs are absolutely contraindicated or used with extreme caution in patients receiving Stellaria Media injections. Beta-blockers can make a patient 'refractory' to epinephrine. If the patient has an anaphylactic reaction to the extract, the standard doses of epinephrine may not work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These medications can interfere with the body's ability to degrade kinins, potentially worsening the severity of an allergic reaction or increasing the risk of angioedema during immunotherapy.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of the sympathomimetic drugs (like epinephrine) used to treat a reaction, leading to a hypertensive crisis.

• Antihistamines: While not dangerous, taking a high-dose antihistamine before a diagnostic skin test will cause a 'false negative' result. Antihistamines should be discontinued 3 to 7 days before testing.
• Systemic Corticosteroids: Long-term use of prednisone may suppress the skin's reactivity to the extract, leading to inaccurate diagnostic results.

• Alcohol: As noted, alcohol can increase the risk of systemic reactions by increasing blood flow and absorption rates.
• High-Fat Meals: There is no direct evidence that food affects the subcutaneous absorption of Stellaria Media, but heavy meals may complicate the management of gastrointestinal symptoms during anaphylaxis.

• St. John's Wort: May theoretically affect the inflammatory threshold, though clinical data is lacking.
• Herbal Stimulants (Ephedra, Guarana): May increase heart rate and complicate the clinical picture if a systemic reaction occurs.

• Skin Tests: Stellaria Media will interfere with other skin tests being performed simultaneously if the reactions are so large they overlap.
• Total IgE: Immunotherapy may cause a transient increase in total IgE levels before they eventually decline.

Mechanism of Interaction: The primary mechanism for most interactions with Stellaria Media is pharmacodynamic. For instance, beta-blockers block the beta-adrenergic receptors that epinephrine needs to stimulate to reverse airway constriction and low blood pressure. This does not change the level of the drug in the blood, but it changes how the body responds to the drug's most dangerous side effect.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Stellaria Media extracts must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted value are at an unacceptably high risk for a fatal bronchospasm if a systemic reaction occurs.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be able to withstand the stress of a systemic reaction or the high-dose epinephrine required to treat it.
3. 3Hypersensitivity to Diluents: Some extracts contain phenol or glycerin. Patients with a known severe allergy to these preservatives must not receive the extract.
4. 4Beta-Blocker Therapy: As previously mentioned, due to the risk of epinephrine resistance.

These conditions require a careful risk-benefit analysis by the physician:

• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system with allergenic extracts could worsen conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Patients undergoing active chemotherapy may have unpredictable immune responses.
• Severe Atopic Dermatitis: May make skin testing results impossible to interpret.
• Pregnancy (Initiation): While maintenance immunotherapy is often continued during pregnancy, starting a new course of Stellaria Media is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia.

Patients allergic to Stellaria Media may also show cross-reactivity to other members of the Caryophyllaceae family (such as Dianthus or Silene). There is also some documented cross-reactivity with certain weed pollens and profilin proteins found in various fruits and vegetables. This is known as Pollen-Food Allergy Syndrome (PFAS).

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Stellaria Media.

FDA Pregnancy Category C (for most allergenic extracts). There are no adequate and well-controlled studies in pregnant women.

• Risks: The primary risk to the fetus is maternal anaphylaxis, which can lead to uterine contractions, placental abruption, or fetal hypoxia (lack of oxygen).
• Clinical Guidance: The American Academy of Allergy, Asthma & Immunology (AAAAI) suggests that immunotherapy doses should not be increased during pregnancy. If a patient is already on a stable maintenance dose and is tolerating it well, the therapy may be continued. However, initiating Stellaria Media therapy during pregnancy is not recommended.

It is not known whether the allergenic proteins in Stellaria Media are excreted in human milk. However, because these are large proteins that are likely degraded in the mother's lymphatic system, the risk to the nursing infant is considered minimal. The decision to continue immunotherapy while breastfeeding should be made based on the mother's clinical need for the treatment.

Stellaria Media is approved for use in the pediatric population, typically for children 5 years of age and older. The efficacy is similar to that in adults. Special care must be taken to ensure the child can communicate early symptoms of a systemic reaction (e.g., 'my throat feels funny' or 'my palms are itchy'). Long-term studies have shown that allergen immunotherapy in children may actually prevent the development of new sensitivities and reduce the risk of progressing from allergic rhinitis to asthma.

Elderly patients may be at higher risk for complications from Stellaria Media therapy.

• Cardiovascular Health: Pre-existing coronary artery disease increases the risk of a reaction being fatal.
• Polypharmacy: Older adults are more likely to be taking interacting medications like ACE inhibitors or beta-blockers.
• Pharmacokinetics: While the processing of the allergen itself doesn't change much with age, the body's compensatory mechanisms (like the 'fight or flight' response to low blood pressure) are often diminished.

No specific studies have been conducted in patients with renal impairment. However, since the clearance of the proteins is via local proteolysis and not primarily through glomerular filtration, the standard dosing protocol is generally followed. Caution is advised in patients on dialysis due to overall physiological fragility.

No dosage adjustments are required. The liver's metabolic capacity does not affect the potency or safety of Stellaria Media allergenic extracts.

> Important: Special populations require individualized medical assessment.

Stellaria Media extracts function as an immunomodulator. In a sensitized individual, the initial exposure to the extract's proteins (allergens) triggers a Type I hypersensitivity reaction mediated by IgE.

When used therapeutically in SCIT (Subcutaneous Immunotherapy), the mechanism involves:

1. 1T-Cell Desensitization: Reducing the activity of Th2 cells that produce IL-4 and IL-5.
2. 2Induction of Regulatory T-Cells: These cells produce IL-10 and TGF-beta, which suppress allergic inflammation.
3. 3B-Cell Switch: Shifting B-cell production from IgE to IgG4. IgG4 acts as a 'blocking antibody' that prevents the allergen from reaching the IgE on mast cells.

• Onset of Action: For diagnostic testing, the onset is 15-20 minutes (the 'immediate phase'). For immunotherapy, clinical improvement typically takes 3 to 6 months of consistent treatment.
• Duration of Effect: The diagnostic wheal disappears within hours. The therapeutic effect of a full course of immunotherapy can last for several years after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous) |

| Protein Binding | Minimal (Local uptake by APCs) |

| Half-life | Variable (Proteins degraded in hours; immune effect lasts years) |

| Tmax | 15-30 minutes for systemic absorption |

| Metabolism | Local Proteolysis |

| Excretion | Renal (as amino acid metabolites) |

• Molecular Formula: Complex mixture of proteins (e.g., profilins, polcalcins).
• Molecular Weight: Ranges from 10 kDa to 70 kDa for major allergenic fractions.
• Solubility: Highly soluble in aqueous saline and glycerin solutions.
• Composition: Contains various saponins (e.g., ginsenoside-like), flavonoids (rutin), and minerals (calcium, magnesium). The 'Standardized Chemical Allergen' EPC designation refers to the specific protein content calibrated for biological activity.

Stellaria Media is classified as a Standardized Chemical Allergen [EPC]. It is grouped with other weed and herb extracts used in allergy medicine. It is distinct from antihistamines or corticosteroids because it modifies the underlying disease process rather than just masking the symptoms.